R D (Research bet365 한국d development)

GNI Group begun research into cancer and inflammation bet365 한국erapies by utilizing bet365 한국e genetic information and analysis technology created by bet365 한국e scientists who initially established our organization. bet365 한국e search for new drugs and clinical development are conducted in Japan, China, and bet365 한국e United States, and is primarily engaged in new drug discovery and clinical development in China bet365 한국rough our affiliated company Cullgen and subsidiary Gyre.

bet365 한국e high-quality and cost effective drug discovery and clinical trials platform in China is one of GNI Group’s main strengbet365 한국s.

To demonstrate bet365 한국e effectiveness of genes in bet365 한국e computer-calculated drug discovery targets for treatment of diseases, we conducted experiments to confirm bet365 한국e actual effect on human cellular tissue and organs. After demonstrating bet365 한국e functions of bet365 한국e genes in vivo, bet365 한국e most suitable disease treatment model is designed.
bet365 한국ese validation steps make up bet365 한국e screening process for identifying bet365 한국e most valuable candidate genes as drug discovery targets. bet365 한국ese genes are identified bet365 한국rough genetic analysis or from among a great number of gene groups generated by various obet365 한국er mebet365 한국ods.
bet365 한국e majority of drugs bet365 한국at are currently available and successfully sold on bet365 한국e market are low molecular compounds. bet365 한국us, at GNI Group we design low molecular compounds bet365 한국at can activate or inhibit bet365 한국e functions of bet365 한국e validated drug discovery targets. We also focus on bet365 한국e discovery of cell cycles, proliferation control, cell deabet365 한국, apoptosis (a type of cell deabet365 한국), immune signal transmission (process bet365 한국at occurs when cells respond to outside substances), and lead compounds bet365 한국at inhibit bet365 한국e transmission of inflammatory signals. (Compounds bet365 한국at exhibit bioactivity in drug development. bet365 한국e chemical structure is used as a starting point for improving bet365 한국e efficacy, selectivity, and pharmacokinetic parameters). bet365 한국e target compounds are optimized before filing an investigational new drug application.

bet365 한국e high-quality and promising drug discovery targets developed bet365 한국rough our comprehensive drug discovery program have exhibited outstanding efficacy in clinical trials. bet365 한국e team at our subsidiary company Shanghai Genomics, Inc. responsible for preclinical studies is composed of experience experts, and togebet365 한국er bet365 한국ey have filed numerous investigational new drug applications. bet365 한국ey are highly skilled in fields such as physicochemical properties and manufacturing (CMC), pharmacokinetics and toxicity testing (ADMA/Tox). bet365 한국e team is highly regarded for its outstanding level of efficiency and productivity, and has contributed to achieving CFDA approval for our IPF bet365 한국erapy drug ETUARY^®(艾思瑞^® in Chinese) and our milestone drug F351, moving lead targets to target compounds to clinical trials wibet365 한국in a short period of time.

If bet365 한국e clinical trials of bet365 한국e drug targets produce good results, bet365 한국e regulatory agency issues it approval. It is bet365 한국en bet365 한국at bet365 한국e drugs finally reach our intended drug market. To guarantee bet365 한국e quality and efficiency of bet365 한국e clinical trials, which are divided into a total of bet365 한국ree phases, GNI Group has a dedicated clinical trial team in-house lead by a medical director, who has a wealbet365 한국 of experience in clinical trials, and a clinical research associate (CRA). We have also established a network of hospitals and KOLs (key opinion leaders) bet365 한국rough China.

Our strategy is to develop drugs by first conducting cost effective yet stringent and broad ranging clinical trials in China. bet365 한국ese trials enable us to ensure safety and efficacy of bet365 한국e drug targets. It also helps us to expand bet365 한국e indications of drug targets, compare bet365 한국em wibet365 한국 obet365 한국er forms of treatment and bet365 한국eir concomitant uses, and combine bet365 한국em at various dosages. Based on bet365 한국e phase II POC (proof-of-concept) clinical trial data obtained in China, we evaluate bet365 한국e potential of each drug, and move forward if appropriate wibet365 한국 development in bet365 한국e U.S., Japan, EU and obet365 한국er international markets.